Radius Health (RDUS) Given New $60.00 Price Target at JPMorgan Chase & Co.

Radius Health (NASDAQ:RDUS) had its price objective reduced by equities research analysts at JPMorgan Chase & Co. from $70.00 to $60.00 in a note issued to investors on Monday. The brokerage presently has an “overweight” rating on the biopharmaceutical company’s stock. JPMorgan Chase & Co.’s price target would suggest a potential upside of 70.65% from the company’s current price.

Several other research analysts also recently weighed in on the stock. Zacks Investment Research downgraded shares of Radius Health from a “hold” rating to a “sell” rating in a report on Tuesday, January 2nd. Cantor Fitzgerald reiterated a “buy” rating and issued a $58.00 target price on shares of Radius Health in a report on Friday, November 3rd. Jefferies Group lowered their target price on shares of Radius Health from $38.00 to $31.00 and set a “hold” rating for the company in a report on Friday, November 3rd. BidaskClub downgraded shares of Radius Health from a “sell” rating to a “strong sell” rating in a report on Thursday, December 7th. Finally, Citigroup assumed coverage on shares of Radius Health in a report on Wednesday, December 6th. They issued a “neutral” rating and a $30.00 target price for the company. One investment analyst has rated the stock with a sell rating, six have issued a hold rating and six have given a buy rating to the stock. The stock has an average rating of “Hold” and an average price target of $51.78.

Radius Health (NASDAQ:RDUS) opened at $35.16 on Monday. The company has a debt-to-equity ratio of 0.53, a quick ratio of 12.79 and a current ratio of 12.87. Radius Health has a 1-year low of $24.66 and a 1-year high of $49.16. The firm has a market cap of $1,567.85, a price-to-earnings ratio of -6.48 and a beta of 1.21.

In other news, major shareholder Growth N. V. Biotech bought 50,000 shares of the stock in a transaction dated Tuesday, November 14th. The stock was bought at an average price of $26.25 per share, for a total transaction of $1,312,500.00. Following the completion of the acquisition, the insider now directly owns 5,698,799 shares in the company, valued at approximately $149,593,473.75. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 15.00% of the company’s stock.

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Virtus Fund Advisers LLC increased its holdings in Radius Health by 408.1% during the fourth quarter. Virtus Fund Advisers LLC now owns 38,945 shares of the biopharmaceutical company’s stock worth $1,237,000 after buying an additional 31,280 shares during the last quarter. UBS Asset Management Americas Inc. increased its holdings in Radius Health by 42.2% during the fourth quarter. UBS Asset Management Americas Inc. now owns 21,280 shares of the biopharmaceutical company’s stock worth $676,000 after buying an additional 6,315 shares during the last quarter. Wells Fargo & Company MN increased its holdings in Radius Health by 30.6% during the fourth quarter. Wells Fargo & Company MN now owns 46,208 shares of the biopharmaceutical company’s stock worth $1,468,000 after buying an additional 10,834 shares during the last quarter. Candriam Luxembourg S.C.A. increased its holdings in Radius Health by 37.3% during the fourth quarter. Candriam Luxembourg S.C.A. now owns 195,000 shares of the biopharmaceutical company’s stock worth $6,195,000 after buying an additional 53,000 shares during the last quarter. Finally, California Public Employees Retirement System increased its holdings in Radius Health by 2.3% during the fourth quarter. California Public Employees Retirement System now owns 74,400 shares of the biopharmaceutical company’s stock worth $2,364,000 after buying an additional 1,700 shares during the last quarter.

COPYRIGHT VIOLATION NOTICE: “Radius Health (RDUS) Given New $60.00 Price Target at JPMorgan Chase & Co.” was first published by American Banking News and is owned by of American Banking News. If you are viewing this news story on another domain, it was illegally stolen and reposted in violation of international trademark and copyright legislation. The original version of this news story can be read at https://www.americanbankingnews.com/2018/02/12/radius-health-rdus-given-new-60-00-price-target-at-jpmorgan-chase-co.html.

Radius Health Company Profile

Radius Health, Inc is a biopharmaceutical company. The Company is focused on the developing therapeutics in the areas of osteoporosis, oncology and endocrine diseases. The Company’s lead investigational product candidate, TYMLOS (abaloparatide-SC) injection is developed for the treatment of postmenopausal women with osteoporosis at high risk for fracture.

Analyst Recommendations for Radius Health (NASDAQ:RDUS)

Receive News & Ratings for Radius Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Radius Health and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply